Solventum (NYSE:SOLV) Price Target Raised to $79.00 at UBS Group

Solventum (NYSE:SOLV) had its price target upped by investment analysts at UBS Group from $77.00 to $79.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price objective would indicate a potential upside of 9.65% from the company’s current price.

A number of other equities research analysts have also commented on SOLV. Wells Fargo & Company increased their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. Piper Sandler boosted their price target on shares of Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $85.56.

Solventum Stock Up 0.7%

SOLV stock traded up $0.53 during midday trading on Monday, reaching $72.05. 569,236 shares of the company’s stock traded hands, compared to its average volume of 1,071,628. Solventum has a 52 week low of $60.70 and a 52 week high of $85.92. The company has a market cap of $12.50 billion, a price-to-earnings ratio of 8.30, a P/E/G ratio of 2.88 and a beta of 0.49. The firm’s fifty day moving average price is $71.97 and its 200-day moving average price is $72.48. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.05 billion. During the same period in the previous year, the firm posted $1.64 earnings per share. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, sell-side analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its stake in Solventum by 0.6% in the second quarter. Nisa Investment Advisors LLC now owns 33,974 shares of the company’s stock valued at $2,577,000 after purchasing an additional 210 shares during the period. South Dakota Investment Council boosted its holdings in Solventum by 3.6% in the 2nd quarter. South Dakota Investment Council now owns 255,625 shares of the company’s stock valued at $19,387,000 after purchasing an additional 8,960 shares in the last quarter. Chelsea Counsel Co. lifted its holdings in shares of Solventum by 720.7% in the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock valued at $804,000 after buying an additional 9,304 shares during the period. ST Germain D J Co. Inc. boosted its stake in shares of Solventum by 84.6% in the second quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock valued at $63,000 after buying an additional 378 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in Solventum during the second quarter worth $3,076,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.